{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:26:30Z","timestamp":1786998390413,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016728","name":"Kyoto Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.xphs.2025.103828","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T11:32:48Z","timestamp":1747049568000},"page":"103828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chronopharmacokinetic model analysis of 5-fluorouracil following S-1 administration in rats: comparison with infusion and other prodrugs for chronochemotherapy"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4694-4651","authenticated-orcid":false,"given":"Shinji","family":"Kobuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2025.103828_bib0001","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","article-title":"Therapeutic drug monitoring of 5-fluorouracil","volume":"78","author":"Lee","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.xphs.2025.103828_bib0002","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jnci\/djp328","article-title":"Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes","volume":"101","author":"Saif","year":"2009","journal-title":"J Natl Cancer Ins"},{"key":"10.1016\/j.xphs.2025.103828_bib0003","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.xphs.2025.103828_bib0004","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/cpt.1124","article-title":"Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy","volume":"10","author":"Beumer","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2025.103828_bib0005","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.bjp.0705651","article-title":"Circadian rhythm of dihydrouracil\/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels","volume":"141","author":"Jiang","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.xphs.2025.103828_bib0006","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7150\/ijms.7.48","article-title":"Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with stage III\/IVa esophageal squamous cell carcinoma","volume":"7","author":"Kuwahara","year":"2010","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.xphs.2025.103828_bib0007","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1002\/ijc.33422","article-title":"Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the International EORTC 05011 Trial","volume":"148","author":"Innominato","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.xphs.2025.103828_bib0008","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/cpt.3181","article-title":"Personalized chronomodulated 5-fluorouracil treatment: a physiologically-based pharmacokinetic precision dosing approach for optimizing cancer therapy","volume":"115","author":"Marok","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2025.103828_bib0009","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(97)03358-8","article-title":"Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International organization for cancer chronotherapy","volume":"350","author":"L\u00e9vi","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.xphs.2025.103828_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12885-015-1075-6","article-title":"Circadian variation in plasma 5-fluorouracil concentrations during a 24 h constant-rate infusion","volume":"15","author":"Fleming","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xphs.2025.103828_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","article-title":"Japanese society for cancer of the colon and rectum. japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer","volume":"25","author":"Hashiguchi","year":"2020","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"10.1016\/j.xphs.2025.103828_bib0012","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/j.1349-7006.2008.00773.x","article-title":"CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1","volume":"99","author":"Fujita","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.xphs.2025.103828_bib0013","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejps.2017.11.021","article-title":"Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats","volume":"112","author":"Kobuchi","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.103828_bib0014","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ejps.2018.08.004","article-title":"Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats","volume":"123","author":"Kobuchi","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.103828_bib0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/07487304221148779","article-title":"Diurnal changes in capecitabine clock-controlled metabolism enzymes are responsible for its pharmacokinetics in male mice","volume":"38","author":"Akyel","year":"2023","journal-title":"J Biol Rhythms"},{"key":"10.1016\/j.xphs.2025.103828_bib0016","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11095-020-02828-6","article-title":"Phase I pharmacological study of continuous chronomodulated capecitabine treatment","volume":"37","author":"Roosendaal","year":"2020","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2025.103828_bib0017","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/00498254.2015.1100767","article-title":"Population pharmacokinetic modelling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats","volume":"46","author":"Kobuchi","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1016\/j.xphs.2025.103828_bib0018","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.xphs.2020.04.005","article-title":"Population pharmacokinetic model-based evaluation of circadian variations in plasma 5-fluorouracil concentrations during long-term infusion in rats: a comparison with oral anticancer prodrugs","volume":"109","author":"Kobuchi","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.103828_bib0019","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3390\/molecules22091488","article-title":"Effect of Sipjeondaebo-Tang on the pharmacokinetics of S-1, an anticancer agent, in rats evaluated by population pharmacokinetic modeling","volume":"22","author":"Kim","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.xphs.2025.103828_bib0020","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/00498254.2023.2283736","article-title":"Pharmacokinetic evaluation of oxaliplatin combined with S-1 (SOX) chemotherapy in a rat model of colorectal cancer with acute kidney injury: predictive renal biomarkers for dose optimisation","volume":"53","author":"Tanaka","year":"2023","journal-title":"Xenobiotica"},{"key":"10.1016\/j.xphs.2025.103828_bib0021","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jpba.2010.01.026","article-title":"Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry","volume":"52","author":"Liu","year":"2010","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2025.103828_bib0022","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2133\/dmpk.22.162","article-title":"Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium","volume":"22","author":"Inoue","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.xphs.2025.103828_bib0023","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.clpt.6100297","article-title":"Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients","volume":"83","author":"MC","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2025.103828_bib0024","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.21873\/anticanres.14683","article-title":"Application of pharmacometrics of 5-fluorouracil to personalized medicine: a tool for predicting pharmacokinetic-pharmacodynamic\/toxicodynamic responses","volume":"40","author":"Kobuchi","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.xphs.2025.103828_bib0025","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1211\/jpp.61.12.0009","article-title":"Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats","volume":"61","author":"Yoshisue","year":"2009","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.xphs.2025.103828_bib0026","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1248\/bpb.b12-00819","article-title":"Pre-therapeutic assessment of plasma dihydrouracil\/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer","volume":"36","author":"Kobuchi","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.xphs.2025.103828_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149813","article-title":"Circadian rhythms in CYP2A5 expression underlie the time-dependent effect of tegafur on breast cancer","volume":"708","author":"Yoshida","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.xphs.2025.103828_bib0028","first-page":"794","article-title":"Rat cytochrome p450 1A and 3A enzymes involved in bioactivation of tegafur to 5-fluorouracil and autoinduced by tegafur in liver microsomes","volume":"29","author":"Yamazaki","year":"2001","journal-title":"Drug Metab Dispos"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925002813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925002813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:05:54Z","timestamp":1751601954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925002813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0022354925002813"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103828","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronopharmacokinetic model analysis of 5-fluorouracil following S-1 administration in rats: comparison with infusion and other prodrugs for chronochemotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103828","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103828"}}